8-K: TScan Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results, Highlights Clinical Progress and Secures Funding

TScan Therapeutics reports financial results for Q4 and full year 2024, showcasing clinical advancements in its ALLOHA and PLEXI-T trials, and securing financial runway into Q1 2027.

Summary

• TScan Therapeutics reported its financial results for the fourth quarter and full year ended December 31, 2024.
• The company presented updated data from the ALLOHA Phase 1 heme trial at the ASH Annual Meeting.
• The IND application was cleared for the seventh TCR in the PLEXI-T Phase 1 solid tumor program, specifically TSC-202-A0201 targeting MAGE-A4 on HLA-A*02:01.
• TScan closed a $30 million registered direct offering at a 37% premium with a long-standing, supportive shareholder.
• The company's cash, cash equivalents, and marketable securities are expected to fund operations into the first quarter of 2027.
• Revenue for Q4 2024 was $0.7 million, compared to $7.2 million for Q4 2023, and $2.8 million for the full year 2024, compared to $21.0 million for the full year 2023.
• Research and development expenses for Q4 2024 were $29.4 million, compared to $22.4 million for Q4 2023, and $107.4 million for the full year 2024, compared to $88.2 million for the full year 2023.
• General and administrative expenses for Q4 2024 were $8.0 million, compared to $6.2 million for Q4 2023, and $30.3 million for the full year 2024, compared to $26.4 million for the full year 2023.
• Net loss was $35.8 million for Q4 2024, compared to $19.6 million for Q4 2023.
• Net loss for the full year 2024 was $127.5 million, compared to $89.2 million for the full year 2023.
• As of December 31, 2024, cash, cash equivalents, and marketable securities totaled $290.1 million, excluding $5.0 million of restricted cash.

Sentiment

Score: 7

Explanation: The document presents a mixed picture. While the company has made significant clinical progress and secured funding, revenue is down and net losses have increased. The positive clinical data and extended cash runway contribute to a moderately positive sentiment.

Positives

• The ALLOHA trial data presented at ASH showed a lower relapse rate in the treatment arm (8%) compared to the control arm (33%).
• The company's cash runway extends into the first quarter of 2027, providing financial stability for ongoing research and development.
• The $30 million registered direct offering was completed at a 37% premium, indicating strong investor confidence.
• The non-dilutive term loan from Silicon Valley Bank provides financial flexibility with interest-only payments through September 2027.
• The FDA clearance of the IND application for TSC-202-A0201 expands the PLEXI-T solid tumor program.

Negatives

• Revenue decreased significantly in both Q4 2024 and full year 2024 compared to the same periods in 2023, primarily due to the timing of research activities with collaboration agreements.
• Net loss increased in both Q4 2024 and full year 2024 compared to the same periods in 2023.
• Research and development expenses increased in both Q4 2024 and full year 2024 compared to the same periods in 2023, driven by increased clinical study expenses and personnel expenses.

Risks

• The company's future success depends on the successful development and commercialization of its TCR-T therapy product candidates, which are subject to clinical trial risks and regulatory approvals.
• The company faces competition from other biotechnology companies developing cancer therapies.
• The company's financial performance is subject to risks related to its collaboration agreements and ability to secure additional funding.
• The company's forward-looking statements are subject to various risks and uncertainties, including those related to clinical trial results, regulatory approvals, and market conditions.

Future Outlook

TScan anticipates several milestones in the near future, including presenting additional data from the ALLOHA Phase 1 trial, initiating a registration trial for TSC-101, filing an IND for TSC-102-A0301, dosing the first patient with multiplex TCR-T therapy, and sharing safety and response data for multiplex therapy.

Management Comments

• The progress we achieved across our pipeline in 2024 has paved the way for a transformative year ahead, said Gavin MacBeath, Ph.D., Chief Executive Officer.
• We are encouraged by the ALLOHA heme data presented at ASH with only 2 of 26 patients having relapsed compared to 4 of 12 control-arm subjects.
• We look forward to presenting additional data from the Phase 1 trial by the end of the year, including two-year relapse data on the initial patients.
• For the PLEXI-T solid tumor program, we continue to enroll patients investigating seven different TCR-Ts, including the recently added MAGE-A4 TCR-T (TSC-202-A0201).
• We look forward to treating our first patient with multiplex therapy in the first half of 2025 and sharing safety and response data for multiplex therapy in the second half of the year.

Industry Context

TScan's focus on TCR-T therapies aligns with the growing interest in personalized cancer treatments and the potential of leveraging the immune system to fight cancer. The company's ImmunoBank approach, which aims to address tumor heterogeneity and resistance, is a notable strategy in the field of cell therapy.

Comparison to Industry Standards

• The ALLOHA trial results, with an 8% relapse rate in the treatment arm compared to 33% in the control arm, are competitive with other cell therapies targeting post-transplant relapse in hematologic malignancies.
• Companies like Atara Biotherapeutics and Adaptimmune Therapeutics are also developing TCR-T therapies, but TScan's ImmunoBank approach and multiplexing strategy differentiate it from some competitors.
• The $290.1 million cash position provides a runway into Q1 2027, which is a strong financial position compared to many other clinical-stage biotech companies.

Stakeholder Impact

• Shareholders benefit from the extended cash runway and positive clinical trial data.
• Employees are recognized through the company being named a Top Place to Work in Massachusetts.
• Patients with cancer may benefit from the development of new TCR-T therapies.

Next Steps

• Continue development of TSC-101 only, as TSC-101 enables treatment of ~98% of patients with HLA type A*02:01.
• Initiate a registration trial for TSC-101, pending further feedback from regulatory authorities, in the second half of 2025.
• Present additional data from the Phase 1 trial by the end of the year, including two-year relapse data on the initial patients.
• File an investigational new drug (IND) application for TSC-102-A0301, a TCR-T targeting CD45 on HLA-A*03:01, in the second half of 2025.
• Progress through initial dose levels across the TCR-T therapy candidates.
• Dose first patient with multiplex TCR-T therapy in the first half of 2025.
• Share safety and response data for multiplex TCR-T therapy anticipated in the second half of 2025.

Key Dates